SEC Form 4 research
| Issuer | Kiniksa Pharmaceuticals International, plc |
|---|---|
| Tickers | KNSA |
| Reporting owners | 37 |
| Officers and directors | 5 |
| Last public filing | 2026-09-04 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-09-03 | 2026-09-01 | Moat Ross | A | 36,950 | $0 | Not reported |
| 2026-09-03 | 2026-09-01 | Moat Ross | A | 9,250 | $0 | Not reported |
| 2026-09-03 | 2026-09-01 | Ragosa Mark | A | 31,150 | $0 | Not reported |
| 2026-09-03 | 2026-09-01 | Ragosa Mark | A | 7,800 | $0 | Not reported |
| 2026-09-03 | 2026-09-01 | Paolini John F. | A | 26,750 | $0 | Not reported |
| 2026-09-03 | 2026-09-01 | Paolini John F. | A | 6,700 | $0 | Not reported |
| 2026-09-03 | 2026-09-01 | Patel Sanj K | A | 120,150 | $0 | Not reported |
| 2026-09-03 | 2026-09-01 | Patel Sanj K | A | 30,050 | $0 | Not reported |
| 2026-09-03 | 2026-09-01 | Patel Sanj K | A | 120,150 | $0 | Not reported |
| 2026-09-03 | 2026-09-01 | Patel Sanj K | A | 30,050 | $0 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.